Lubiprostone: In constipation-predominant irritable bowel syndrome

Drugs

Volumn 69, Issue 9, 2009, Pages 1229-1237

  Carter, Natalie J ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

LUBIPROSTONE; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANAPHYLAXIS; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; CHEST TIGHTNESS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; ERUCTATION; ERYTHEMA; FATIGUE; FECES INCONTINENCE; FIBROMYALGIA; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TRACT FUNCTION; HARD FECES; HEALTH STATUS; HEART PALPITATION; HUMAN; IRRITABLE COLON; LETHARGY; LOOSE FECES; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; POLLAKISURIA; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REVIEW; SIDE EFFECT; THORAX PAIN; THROAT TIGHTNESS; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ALPROSTADIL; CLINICAL TRIALS, PHASE III AS TOPIC; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IRRITABLE BOWEL SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67649347908     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-200969090-00007     Document Type: Review

References (26)

1. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 Dec; 123 (6): 2108-31
2. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006 Apr; 130 (5): 1480-91
3. Mayer EA. Irritable bowel syndrome. N Engl J Med 2008 Apr; 358 (16): 1692-9
4. Saad R, Chey WD. Irritable bowel syndrome with constipation among older adults. Geriatr Aging 2007 Feb; 10 (2): 84-90
5. Ginzburg R, Ambizas EM. Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders. Expert Opin Drug Metab Toxicol 2008 Aug; 4 (8): 1091-7
6. Andresen V, Camilleri M. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs 2006; 66 (8): 1073-88
7. Wagstaff AJ, Frampton JE, Croom KF. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs 2003; 63 (11): 1101-20
8. US FDA. FDA permits restricted use of Zelnorm for qualifying patients [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108956.htm [Accessed 2009 Jun 2]
9. US FDA. Tegaserod maleate (marketed as Zelnorm) [online]. Available from URL: http://www.fda.gov/Drugs/ DrugSafety/DrugSafetyNewsletter/ucm051284.html [Accessed 2009 Jun 2]
10. US FDA. Questions and answers about the voluntary discontinuation of Zelnorm's (tegaserod maleate) treatment investigational new drug (IND) [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/zelnorm/QA-2008.htm [Accessed 2009 Jan 5]
11. Sucampo Pharmaceuticals Inc. Highlights of US prescribing information: Amitiza® (lubiprostone) capsules [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/021908s005lbl.pdf [Accessed 2009 Jun 2]
12. McKeage K, Plosker GL, Siddiqui MAA. Lubiprostone. Drugs 2006; 66 (6): 873-9
13. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human CIC-2 chloride currents. Am J Physiol Cell Physiol 2004 Nov; 287 (5): C1173-83
14. Rivera E, Wahle A, Joswick TR, et al. Lubiprostone, a novel type-2 chloride channel (Clc-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation [abstract no. S1188]. Gastroenterology 2007 Apr; 132 (4 Suppl. 2): A191-2
15. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006 May; 290 (5): G942-7
16. Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009 Feb; 296 (2): G295-301
17. Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008May; 154 (1): 126-35
18. Moeser AJ, Nighot PK, Engelke KJ, et al. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the CIC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007 Feb; 292 (2): G647-56
19. Johanson JF,DrossmanDA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.Aliment Pharmacol Ther 2008Apr; 27 (8): 685-96
20. ClinicalTrials.gov. Efficacy and safety of lubiprostone in patients with irritable bowel syndrome with constipation [ClinicalTrials.gov indentifier NCT00380250]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ [Accessed 2009 Jun 2]
21. ClinicalTrials.gov. Efficacy and safety of lubiprostone in patients with irritable bowel syndrome with constipation [ClinicalTrials.gov indentifier NCT00399542]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ [Accessed 2009 Jun 2]
22. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebocontrolled studies. Aliment Pharmacol Ther 2009 Feb; 29 (3): 329-41
23. Chey WD, Saad RJ, Panas RM, et al. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: results from a randomized withdrawal study [abstract no. M1706]. Gastroenterology 2008 Apr; 134 (4 Suppl. 1): A401
24. Chey WD, Drossman DA, Scott C, et al. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation [abstract no. S1272]. Gastroenterology 2008 Apr; 134 (4 Suppl. 1): A215
25. US FDA. Summary review: Amitiza® (lubiprostone) capsules for the treatment of irritable bowel syndrome with constipation in women ≥18 years old [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/ summary-review/2008/021908se1-005-SUMR.pdf [Accessed 2009 Jun 2]
26. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 Sep; 45 Suppl. 2: II43-7